QKR may slow down the progress of AD by alleviating the level of Aβ, improving the cognitive function, and inhibiting apoptosis in the APP/PS1 double transgenic mice via the PI3K/Akt pathway, especially the high dose group of 19 mg/kg/d, which showed almost similar effects with the positive control group of donepezil, an drug with clinical validity certification. This evidence concerns the gene APP and Alzheimer disease.